Results 201 to 210 of about 3,775,993 (302)

Risk of Hepatitis B Virus Reactivation in Patients With Inflammatory Arthritis Receiving Disease‐Modifying Antirheumatic Drugs: A Systematic Review and Meta‐Analysis

Arthritis care & research, 2018
Tzu-Chieh Lin, K. Yoshida, S. Tedeschi, M. M. de Abreu, N. Hashemi, Daniel H Solomon   +5 more
semanticscholar   +1 more source

Peficitinib, a JAK Inhibitor, in Combination With Limited Conventional Synthetic Disease‐Modifying Antirheumatic Drugs in the Treatment of Moderate‐to‐Severe Rheumatoid Arthritis

Arthritis & Rheumatology, 2017
M. Genovese, M. Greenwald, C. Codding, A. Zubrzycka-Sienkiewicz, A. Kivitz, Annie Wang, Kathyjo Shay, Xuegong Wang, J. Garg, M. Cardiel   +9 more
semanticscholar   +1 more source

Personalized dose reduction strategies for biologic disease-modifying antirheumatic drugs for treating axial spondyloarthritis: a clinical and economic evaluation with predictive modeling. [PDF]

BMC Rheumatol
Binh BH, Phuong NTT, Hang VTT, Nhan NTT, Hoa NTN, Van Dung H.   +5 more
europepmc   +1 more source

Long-Standing Untreated or Inadequately Treated Seropositive Rheumatoid Arthritis in the Golden Age of Disease-Modifying Antirheumatic Drugs. [PDF]

Cureus
Arcilla CK, Kaeley GS, Thway M.
europepmc   +1 more source

Monotreatment With Conventional Antirheumatic Drugs or Glucocorticoids in Rheumatoid Arthritis: A Network Meta-Analysis.

JAMA Netw Open, 2023
Guski LS, Jürgens G, Pedder H, Levinsen NKG, Andersen SE, Welton NJ, Graudal N.   +6 more
europepmc   +1 more source

A Case of Oral Mucous Membrane Ulcers Caused by Disease-modifying Antirheumatic Drug (DMARD; Bucillamine)

, 2011
角田 愛美, 荒関 昭博, 高橋 悦子   +2 more
openalex   +2 more sources

Abatacept, Golimumab, and Sarilumab as Selected Bio-Originator Disease-Modifying Antirheumatic Drugs with Diverse Mechanisms of Action in Their Current Use in Treatment. [PDF]

J Clin Med
Kawczak P, Feszak IJ, Bączek T.
europepmc   +1 more source

Diverging effects of tumor necrosis factor inhibitors and conventional synthetic disease-modifying antirheumatic drugs on immunosenescence and inflammageing in rheumatoid arthritis: a cross-sectional analysis. [PDF]

Immun Ageing
Schwarz T, Almanzar G, Völkl S, Feuchtenberger M, Leierer J, Schmidt C, Deininger F, Tony HP, Schmalzing M, Prelog M.   +9 more
europepmc   +1 more source

Faculty Opinions recommendation of Persistence of antibody response 1.5 years after vaccination using 7-valent pneumococcal conjugate vaccine in patients with arthritis treated with different antirheumatic drugs.

, 2013
Direk Limmathurotsakul, Cherry Lim
openalex   +2 more sources

Incidence of Major Adverse Cardiovascular Events in Patients With Rheumatoid Arthritis Treated With JAK Inhibitors Compared With Biologic Disease-Modifying Antirheumatic Drugs: Data From an International Collaboration of Registries. [PDF]

Arthritis Rheumatol
Aymon R, Mongin D, Guemara R, Salis Z, Askling J, Choquette D, Codreanu C, Di Giuseppe D, Flouri I, Huschek D, Hyrich KL, Iannone F, Kvien TK, Leeb BF, Nordström D, Otero-Varela L, Pavelka K, Pombo-Suarez M, Rodrigues A, Rotar Z, Sidiropoulos P, Provan SA, Strangfeld A, Nina T, Zavada J, Kearsley-Fleet L, Courvoisier DS, Finckh A, Lauper K.   +28 more
europepmc   +1 more source